COVID-19疫苗接种后促血栓性免疫性血小板减少症
本文报告5例接种ChAdOx1疫苗(AZD1222)后出现促血栓性免疫性血小板减少症,于首剂接种后5至11天发病,临床表现为脑静脉窦血栓、内脏静脉血栓、动脉性脑血栓栓塞及血栓性微血管病,均伴血小板减少、D-二聚体显著升高及抗PF4抗体阳性。患者血清免疫球蛋白以AZD1222依赖方式结合健康供者血小板,并可被肝素抑制。
要点
- 接种AZD1222后5至11天出现血小板减少伴血栓形成需警惕本病。
- 所有患者抗PF4抗体阳性,但均无肝素暴露史。
- 抗凝单用或联合依库珠单抗/IVIG使3例患者病情缓解。
核心结论
- AZD1222疫苗接种后可发生以血小板减少和AZD1222依赖性抗PF4抗体结合血小板为特征的自身免疫性促血栓性疾病。
研究设计与样本
- 病例系列,报告5例接种AZD1222疫苗后发生促血栓性免疫性血小板减少症的患者。
主要发现
- 患者于首剂接种后5至11天发病。
- 临床表现包括脑静脉窦血栓、内脏静脉血栓、动脉性脑血栓栓塞及血栓性微血管病。
- 所有患者均有血小板减少和D-二聚体显著升高。
- 所有患者检出抗PF4抗体,但均无肝素暴露史。
- 患者血清免疫球蛋白以AZD1222依赖方式结合健康供者血小板,该结合可被肝素抑制。
关键数值与推荐
- 患者血清在缓冲液或AZD1222存在时可聚集健康供者血小板,该聚集可被肝素抑制。
- 抗凝单用或联合依库珠单抗或IVIG使3例患者病情缓解。
- 2例患者在IVIG后血小板上升期间、尽管接受抗凝仍发生血栓栓塞事件。
临床怎么用
- 对AZD1222接种后5至11天出现血小板减少伴血栓形成者,应检测抗PF4抗体。
- 治疗可考虑抗凝联合IVIG或依库珠单抗。
- 即使血小板回升且接受抗凝,仍需警惕血栓栓塞事件复发。
局限性
- 仅为5例病例的初步临床经验,样本量小。
- 原文未报告对照人群或发病率数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report 5 cases of prothrombotic immune thrombocytopenia after exposure to the ChAdOx1 vaccine (AZD1222, Vaxzevria) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients presented 5 to 11 days after first vaccination. The spectrum of clinical manifestations included cerebral venous sinus thrombosis, splanchnic vein thrombosis, arterial cerebral thromboembolism, and thrombotic microangiopathy. All patients had thrombocytopenia and markedly elevated D-dimer. Autoantibodies against platelet factor 4 (PF4) were detected in all patients, although they had never been exposed to heparin. Immunoglobulin from patient sera bound to healthy donor platelets in an AZD1222-dependent manner, suppressed by heparin. Aggregation of healthy donor platelets by patient sera was demonstrated in the presence of buffer or AZD1222 and was also suppressed by heparin. Anticoagulation alone or in combination with eculizumab or intravenous immunoglobulin (IVIG) resolved the pathology in 3 patients. Two patients had thromboembolic events despite anticoagulation at a time when platelets were increasing after IVIG. In summary, an unexpected autoimmune prothrombotic disorder is described after vaccination with AZD1222. It is characterized by thrombocytopenia and anti-PF4 antibodies binding to platelets in AZD1222-dependent manner. Initial clinical experience suggests a risk of unusual and severe thromboembolic events.
引用
- Tiede A, Sachs UJ, Czwalinna A, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021. PMID: 34323939. doi:10.1182/blood.2021011958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。